Table 2 Clinicopathological features of Xp11.2 tRCC patients stratified by the cut-off value of the NLR

Age in years

  > 45

21 (25.6%)

16 (40.0%)

5 (11.9%)

  ≤ 45

61 (74.4%)

24 (60.0%)

37 (88.1%)

Sex

 Male

33 (40.2%)

14 (35.0%)

19 (45.2%)

 Female

49 (59.8%)

26 (65.0%)

23 (54.8%)

Tumour size

5.94 ± 2.65

7.0 ± 3.0

4.0 ± 1.1

Location

 Left

31 (37.8%)

18 (45.0%)

23 (54.8%)

 Right

51 (62.2%)

22 (55.0%)

19 (45.2%)

Symptoms

 Asymptomatic

48 (58.5%)

25 (62.5%)

23 (54.8%)

 Symptomatic

34 (41.5)

15 (37.5%)

19 (45.2%)

Fuhrman grade

 1 to 2

32 (39.0%)

10 (25%)

22 (52.4%)

 3 to 4

50 (61.0%)

30 (75%)

20 (47.6%)

TNM stage

 I-II

49 (59.8%)

14 (35.0%)

35 (83.3%)

 III-IV

33 (40.2%)

26 (65.0%)

7 (16.7%)

pT status

 T1-T2

64 (78.0%)

25 (62.5%)

39 (92.9%)

 T3-T4

18 (22.0%)

15 (37.5%)

3 (7.1%)

pN status

 N0

59 (72.0%)

21 (52.5%)

38 (90.5%)

 N1

23 (28.0%)

19 (47.5%)

4 (9.5%)

pM status

 M0

78 (95.1%)

36 (90.0%)

42 (100.0%)

 M1

4 (4.9%)

4 (10.0%)

0 (0.0%)

Surgical treatment

 Radical

55 (67.1%)

29 (72.5%)

26 (61.9%)

 Partial

27 (32.9)

11 (27.5)

16 (38.1%)

Tumour thrombus

 Negative

72 (87.8%)

31 (77.5%)

41 (97.6%)

 Positive

10 (12.2%)

9 (22.5%)

1 (2.4%)

CRP/Alb

  ≤ 0.083

44 (53.7%)

13 (32.5%)

31 (73.8%)

  > 0.083

38 (46.3%)

27 (67.5%)

11 (26.2%)

PLR

  ≤ 140

46 (56.1%)

15 (37.5%)

31 (73.8%)

  > 140

36 (43.9%)

25 (62.5%)

11 (26.2%)

LDH

 Normal

68 (82.9%)

29 (72.5%)

39 (92.9%)

 Elevated

14 (17.1%)

11 (27.5%)

3 (7.1%)

Proteinuria

 No

63 (76.8%)

26 (65.0%)

37 (88.1%)

 Yes

19 (23.2%)

14 (35.0%)

5 (11.9%)